Biomedical Advanced Research and Development Authority (BARDA)

Vaxxas is a biotechnology company developing needle-free vaccination technology. It uses proprietary dry-coating technology to eliminate or significantly reduce the need for vaccine refrigeration, easing storage and transportation logistics.

Eradivir is a biotechnology company based in West Lafayette, Indiana. Founded in 2020, it focuses on developing a non-immunological targeting agent to combat the virus causing COVID-19.

Enalare Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients suffering from acute respiratory and critical care conditions including respiratory depression caused by drug overdose, post-surgery, and pathogens.

Care Access Research provides clinical research and clinical trial services. Care Access Research goal is to engage every healthcare professional in clinical research and to make clinical trials a care option for every patient.

CastleVax operates as a clinical-stage vaccine research company. CastleVax is reimagining how to provide safe and effective vaccines for all humans, everywhere.

Walgreens is the largest drugstore chain in the United States, operating 7,689 locations across all 50 states, the District of Columbia, and Puerto Rico. The company serves nearly 6 million customers daily, offering convenient access to a wide range of consumer goods, pharmacy services, and health and wellness solutions. Walgreens provides various pharmacy services, including retail, specialty, infusion, medical facility, and mail services, alongside respiratory care. These services aim to enhance health outcomes while reducing costs for various stakeholders, including employers and managed care organizations. A subsidiary of Walgreens, Take Care Health Systems, manages over 700 worksite health centers and in-store clinics, further expanding the company's reach in providing accessible healthcare solutions.

Qpex Biopharma is a San Diego-based biopharmaceutical company founded in 2018, focused on developing innovative therapies to address the growing challenge of antimicrobial resistance. The company specializes in creating a pipeline of antibiotic drugs aimed at treating infectious diseases in both inpatient and outpatient settings. With a strong emphasis on the discovery, development, and regulatory approval of anti-infective medicines, Qpex Biopharma leverages its expertise and experience in collaboration with public and private partnerships to meet critical medical needs. The company's mission is to provide effective solutions for healthcare professionals facing the complexities of resistant infections, thereby enhancing treatment options for patients.

ATCC global biological materials resource and standards organization whose mission focuses on the acquisition, authentication, production, preservation, development, and distribution of standard reference microorganisms, cell lines, and other materials. While maintaining traditional collection materials, ATCC develops high-quality products, standards, and services to support scientific research and breakthroughs that improve the health of global populations.

Battelle is the largest independent research and development organization globally, based in Columbus, Ohio. Established in 1929, it operates as a nonprofit private foundation focused on advancing scientific discovery and innovation. Battelle brings together experts in various fields to foster collaboration between people, science, and technology, aiming to accelerate advancements that benefit society. The organization is governed by a board of directors, ensuring that its resources are directed towards impactful research and development initiatives.

Draper is a non-profit laboratory engaged in applied research, engineering development, education, and technology transfer. It provides engineering services to governments, industries, and academies, acts as a prime contractor or subcontractor on teams, and collaborates in consortia while offering independent assessments of technologies or systems proposed by others. The organization specializes in precision instrumentation, fault-tolerant and autonomous systems, image and data analytics, human systems technology, materials engineering and microfabrication, and biomedical solutions. Draper is based in Cambridge, Massachusetts, and was founded in 1973.

Vir Biotechnology, Inc. is a clinical-stage immunology company based in San Francisco, California, founded in 2016. It specializes in developing innovative therapeutic products aimed at treating and preventing serious infectious diseases. The company's pipeline includes several promising candidates, such as VIR-2218 and VIR-3434 for hepatitis B, VIR-2482 for influenza A, VIR-1111 for HIV, and VIR-2020 for tuberculosis. Vir Biotechnology employs advanced technologies and scientific expertise to manipulate immune responses and enhance pathogen-host interactions. The company has established various collaborations and agreements with notable organizations, including the Bill & Melinda Gates Foundation, National Institutes of Health, and Alnylam Pharmaceuticals, among others. Additionally, it has a manufacturing agreement with Samsung Biologics for the production of SARS-CoV-2 antibodies aimed at potential COVID-19 treatment. Through its innovative approaches, Vir Biotechnology aspires to significantly reduce the burden of infectious diseases in the future.

Rivanna Medical, LLC is a medical technology company founded in 2010 and headquartered in Charlottesville, Virginia. The company specializes in the development and commercialization of Accuro, an advanced ultrasound-based system designed to enhance the application of spinal and epidural anesthesia through automated three-dimensional navigation of the lumbar spine. In addition to its primary focus on anesthesia, Rivanna Medical's technology also encompasses various imaging applications, including diagnostic imaging for musculoskeletal and abdominal anatomies. By leveraging innovative ultrasound technology, Rivanna Medical aims to lower healthcare costs, improve patient outcomes, and minimize the risks associated with radiation from traditional X-ray-based imaging.

Aptitude Medical Systems is a biotechnology research company specializing in molecular recognition technology that utilizes aptamers to address the limitations of traditional antibodies. By developing highly stable and resistant aptamers, the company offers solutions that bind with high affinity and specificity to challenging targets, even discriminating between targets that differ by a single functional group. This innovation enables a range of applications across life sciences, diagnostics, and therapeutics, facilitating the creation of advanced products tailored to meet the stringent demands of molecular recognition. Through its partnerships, Aptitude aims to advance the capabilities of molecular diagnostics and therapeutic interventions.

Sabin Vaccine Institute is dedicated to enhancing vaccine accessibility and promoting immunization, particularly in low- and middle-income populations that are most vulnerable to infectious diseases. The organization focuses on the development of innovative vaccines aimed at preventing a wide range of diseases, thereby improving public health outcomes. By striving to make vaccines available globally, Sabin Vaccine Institute seeks to benefit individuals and communities, ultimately contributing to better healthcare and disease prevention efforts worldwide.

OraSure Technologies, Inc. develops, manufactures, and markets oral fluid diagnostic products and specimen collection devices used for detecting critical medical conditions. The company operates primarily in two segments, focusing on a diverse range of products that include rapid tests for HIV, HCV, and Ebola, as well as drug testing and alcohol testing solutions. Notable offerings include the OraQuick Rapid HIV test, the Intercept Oral Fluid Drug Testing System, and the Q.E.D. Saliva Alcohol Test. Additionally, OraSure provides genomic products through its subsidiary, DNA Genotek, which specializes in oral fluid sample collection for molecular diagnostics. The company's products cater to clinical laboratories, hospitals, community organizations, and government agencies, and are available in pharmacies across multiple continents. Founded in 2000 and headquartered in Bethlehem, Pennsylvania, OraSure Technologies is committed to advancing diagnostic solutions and improving public health outcomes.

T2 Biosystems, Inc. is an in vitro diagnostics company specializing in the rapid detection of pathogens and biomarkers to enhance patient care. The company employs its proprietary T2 Magnetic Resonance technology, which allows for the detection of various pathogens directly from unpurified patient samples, such as whole blood and urine, without the need for extensive sample preparation. T2 Biosystems offers several diagnostic products, including the T2Dx Instrument, which is designed to identify pathogens associated with sepsis and Lyme disease. Its product lineup includes the T2Candida Panel for detecting Candida species, the T2Bacteria Panel for identifying bacterial pathogens, the T2SARS-CoV-2 Panel for COVID-19 testing, and the T2Resistance Panel for detecting antibiotic resistance markers. Founded in 2006 and headquartered in Lexington, Massachusetts, T2 Biosystems aims to improve clinical outcomes and reduce healthcare costs by enabling faster and more accurate diagnostic testing.

Enalare Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients suffering from acute respiratory and critical care conditions including respiratory depression caused by drug overdose, post-surgery, and pathogens.

Sabin Vaccine Institute is dedicated to enhancing vaccine accessibility and promoting immunization, particularly in low- and middle-income populations that are most vulnerable to infectious diseases. The organization focuses on the development of innovative vaccines aimed at preventing a wide range of diseases, thereby improving public health outcomes. By striving to make vaccines available globally, Sabin Vaccine Institute seeks to benefit individuals and communities, ultimately contributing to better healthcare and disease prevention efforts worldwide.

Founded in 2013, Arcturus Therapeutics is a biotechnology company focused on developing RNA medicines for rare diseases, with a current emphasis on liver and respiratory conditions. The company owns proprietary technologies such as UNA chemistry and LUNAR platform, enabling it to target any gene in the human genome.

Spectral AI develops proprietary AI algorithms and optical technology to predict wound healing. Its DeepView® Wound Imaging Solution, an FDA Breakthrough Designated system, uses multispectral imaging to distinguish between non-healing and healing tissue invisible to the naked eye. The company aims to provide 'Day One' healing assessments for burn wounds and diabetic foot ulcers.

EverGlade Consulting is a national consulting firm that offers management consulting solutions. The firm provides government funding, product development, litigation support, CHIPS funding applications, and DOE Loan Program application support solutions. It helps clients navigate the federal landscape. Its company incorporates market-based analytics based on industry, allowing us to focus more on organizational operations.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, focused on developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. Established in 2014, the company utilizes synthetic amplifier technology to enhance the speed and complexity of antibiotic susceptibility testing, thereby significantly improving patient care. By facilitating the rapid selection of personalized antimicrobial therapies, SeLux aims to transform the management of infectious diseases, ultimately saving lives, reducing hospital stays, and combating the growing issue of antibiotic resistance through more targeted treatments.

Visby Medical is a diagnostics company developing PCR-based testing devices and a mobile-enabled health care platform for infectious diseases. Its device platform enables PCR-based diagnostics with results in under 30 minutes and requires no additional instruments or maintenance, supporting point-of-care testing during a single visit. The company pursues a human-centric, technology-first approach to device development and also provides services related to health information, risk assessment, electronic medical records, data privacy and security, data analytics, and remote medical advice for governments, national-level NGOs, and private health providers. Founded in 2008 and based in San Jose, California, Visby Medical aims to improve patient outcomes by enabling rapid, accurate tests at the point of care.

The Stevanato Group S.p.A. is a global manufacturer specializing in packaging containers made from glass tubing, specifically for the pharmaceutical industry. The company focuses on providing high-quality solutions that meet the stringent requirements of pharmaceutical packaging. With a commitment to innovation and quality, Stevanato Group serves a worldwide market, catering to the needs of various stakeholders in the pharmaceutical sector.

Opiant Pharmaceuticals, a specialty pharmaceutical company based in Santa Monica, California, focuses on developing medicines to treat addictions and drug overdoses. Founded in 2005, the company has created NARCAN nasal spray, a widely recognized treatment for reversing opioid overdoses. Opiant's pipeline includes potential treatments for alcohol use disorders, acute cannabinoid overdose, and opioid use disorders. The company leverages intranasal and injectable delivery technologies to address these critical health issues.

Spero Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for multi-drug resistant bacterial infections and rare diseases. Its primary focus is on tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic intended for adult use in treating MDR Gram-negative infections.

Cue Health Inc. is a healthcare technology company based in San Diego, California, specializing in the development and manufacturing of diagnostic screening devices for home use. Founded in 2010, the company offers a connected diagnostic platform known as the Cue Health Monitoring System, which allows users to conduct self-serve tests that provide lab-quality results. This platform enables individuals to track key health indicators, including inflammation, vitamin D, fertility, influenza, and testosterone, through a user-friendly device that connects to a smartphone app. The Cue app not only displays test results but also integrates data on lifestyle factors such as activity and sleep, facilitating a comprehensive view of health at a molecular level. Additionally, Cue Health provides various services for healthcare professionals, including tools for managing patient test histories and telemedicine consultations. The company's innovative approach empowers consumers and healthcare providers alike to access critical health information easily and effectively.

Spectral AI develops proprietary AI algorithms and optical technology to predict wound healing. Its DeepView® Wound Imaging Solution, an FDA Breakthrough Designated system, uses multispectral imaging to distinguish between non-healing and healing tissue invisible to the naked eye. The company aims to provide 'Day One' healing assessments for burn wounds and diabetic foot ulcers.

Basilea Pharmaceutica AG is a commercial-stage biopharmaceutical company based in Basel, Switzerland, focused on developing innovative treatments for severe bacterial and fungal infections, as well as oncology. The company markets isavuconazole, an antifungal drug available in intravenous and oral forms, to treat invasive aspergillosis and mucormycosis. Additionally, Basilea offers ceftobiprole, an intravenous antibiotic for treating community and hospital-acquired pneumonia, and is conducting Phase III clinical trials for its use in acute bacterial skin and skin structure infections, as well as Staphylococcus aureus bacteremia. The company is also advancing several investigational therapies, including Derazantinib, a small molecule inhibitor for intrahepatic cholangiocarcinoma; BAL101553, a tumor checkpoint controller; and BAL3833, a panRAF/SRC kinase inhibitor. With operational subsidiaries in the United Kingdom and Germany, Basilea Pharmaceutica's products are available in multiple countries, including the United States and various European and non-European markets.

Cepheid develops and markets molecular diagnostic systems and tests that automate complex genetic analyses to deliver rapid, actionable results. The company focuses on infectious diseases, cancer, and other conditions where accurate nucleic acid testing is critical, offering on-demand testing across multiple platforms and sample types. Its solutions enable hospitals, clinics, and laboratories of varying sizes to perform rapid molecular testing, including virology, oncology, and sexual health assays, thereby supporting timely diagnosis and treatment decisions.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, focused on developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. Established in 2014, the company utilizes synthetic amplifier technology to enhance the speed and complexity of antibiotic susceptibility testing, thereby significantly improving patient care. By facilitating the rapid selection of personalized antimicrobial therapies, SeLux aims to transform the management of infectious diseases, ultimately saving lives, reducing hospital stays, and combating the growing issue of antibiotic resistance through more targeted treatments.

Spectral AI develops proprietary AI algorithms and optical technology to predict wound healing. Its DeepView® Wound Imaging Solution, an FDA Breakthrough Designated system, uses multispectral imaging to distinguish between non-healing and healing tissue invisible to the naked eye. The company aims to provide 'Day One' healing assessments for burn wounds and diabetic foot ulcers.

Visby Medical is a diagnostics company developing PCR-based testing devices and a mobile-enabled health care platform for infectious diseases. Its device platform enables PCR-based diagnostics with results in under 30 minutes and requires no additional instruments or maintenance, supporting point-of-care testing during a single visit. The company pursues a human-centric, technology-first approach to device development and also provides services related to health information, risk assessment, electronic medical records, data privacy and security, data analytics, and remote medical advice for governments, national-level NGOs, and private health providers. Founded in 2008 and based in San Jose, California, Visby Medical aims to improve patient outcomes by enabling rapid, accurate tests at the point of care.

First Light Diagnostics Inc. is a medical diagnostics company focused on developing automated products for the rapid detection of pathogens responsible for healthcare-associated infections. Based in Chelmsford, Massachusetts, the company offers a benchtop MultiPath analyzer, which is designed for hospital clinical microbiology laboratories and can identify both resistant and sensitive strains of Staphylococcus aureus, as well as various toxins and viruses. Their innovative diagnostic solutions address the increasing demand for accurate and cost-effective testing, which has been shown to significantly reduce hospital infection rates. First Light's proprietary MultiPath detection technology combines the performance of advanced laboratory tests with enhanced affordability and user-friendliness. By providing antimicrobial susceptibility tests that deliver results within hours, the company enables healthcare professionals to administer appropriate antibiotic treatments quickly, ultimately saving lives, reducing healthcare costs, and improving antibiotic stewardship. First Light Diagnostics was incorporated in 2006 and was formerly known as First Light Biosciences Inc. before its name change in January 2019.

Vaxxas is a biotechnology company developing needle-free vaccination technology. It uses proprietary dry-coating technology to eliminate or significantly reduce the need for vaccine refrigeration, easing storage and transportation logistics.

Vedanta Biosciences is a clinical-stage microbiome company focused on developing therapies for immune-mediated and infectious diseases using live bacteria derived from the human microbiome. The company designs orally delivered defined bacterial consortia, leveraging libraries of microbiome-derived strains, proprietary datasets from human interventional studies, and tools for selecting potent strains. Its platform encompasses consortium design and CGMP manufacturing of bacterially defined products, enabling physicians to access live bacteria drugs for autoimmune and inflammatory conditions. Headquartered in Cambridge, Massachusetts, Vedanta Biosciences aims to create a new category of oral therapies arising from defined bacterial communities grown from clonal cell banks.

Moderna is a biotechnology company focused on messenger RNA therapeutics and vaccines. It develops mRNA-based medicines that instruct cells to produce therapeutic proteins or antibodies in vivo, targeting infectious diseases, oncology, cardiovascular diseases, and rare genetic disorders. Founded in 2010 and headquartered in Cambridge, Massachusetts, the company has built a broad pipeline with multiple development candidates across several modalities and a track record highlighted by a COVID-19 vaccine authorized in the United States. Moderna collaborates with major pharmaceutical and research partners, including AstraZeneca, Merck, Vertex, and Alexion, as well as academic institutions such as Harvard University and Karolinska Institutet. It maintains manufacturing collaborations with Lonza for mRNA production and Catalent for fill-finish, and engages with public sector and philanthropic supporters such as BARDA, DARPA, and the Gates Foundation. As of 2025, the company continued expanding its mRNA development program across infectious disease, oncology, cardiovascular, and rare genetic diseases.

QuidelOrtho is a developer, manufacturer and marketer of in vitro diagnostic solutions, including rapid point-of-care tests and other diagnostic assays. The company offers infectious disease and reproductive health testing under brands such as QuickVue and Quidel, with products for influenza, Group A Streptococcus and respiratory syncytial virus, as well as pregnancy, Chlamydia, bacterial vaginosis and bone health tests. Its portfolio also includes immunoassay fecal occult blood tests and Helicobacter pylori serology, along with veterinary products and clinical laboratory and research assays used to measure immune function. QuidelOrtho distributes to physicians, hospitals, clinical laboratories, retail clinics and wellness screening centers through a mix of distributors and direct sales in the United States, supplemented by international distributor networks in Japan, Europe and the Middle East. The company has a global presence with a majority of revenue sourced from North America, and engages in collaborations for molecular diagnostic development using isothermal amplification technology.

Corning Incorporated, headquartered in Corning, New York, is a global leader in manufacturing glass, ceramics, and related materials. Established in 1851, the company operates across several segments, including Display Technologies, Optical Communications, Environmental Technologies, Specialty Materials, and Life Sciences. The Display Technologies segment produces glass substrates for organic light-emitting diodes and liquid crystal displays utilized in televisions and computers. In Optical Communications, Corning provides optical fibers, cables, and various hardware solutions for telecommunications networks. The Environmental Technologies segment focuses on emissions control products for the automotive sector, while Specialty Materials includes advanced formulations for glass and ceramics. The Life Sciences segment offers laboratory products, including consumables and pharmaceutical glass packaging. Corning also develops Gorilla Glass for mobile devices and collaborates with companies like Intel Corporation to enhance technology solutions. Through its diverse product offerings, Corning aims to meet evolving market demands and support innovation in dynamic industries.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, focused on developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. Established in 2014, the company utilizes synthetic amplifier technology to enhance the speed and complexity of antibiotic susceptibility testing, thereby significantly improving patient care. By facilitating the rapid selection of personalized antimicrobial therapies, SeLux aims to transform the management of infectious diseases, ultimately saving lives, reducing hospital stays, and combating the growing issue of antibiotic resistance through more targeted treatments.

RxSight, Inc. is a medical technology company based in Aliso Viejo, California, focused on enhancing vision for patients after cataract surgery. It has developed the RxSight Light Adjustable Lens system, which includes the Light Adjustable Lens (LAL), a Light Delivery Device (LDD), and associated accessories. This innovative technology is the first of its kind to allow healthcare professionals to customize and optimize visual acuity post-surgery, enabling precise reshaping of the lens to meet individual patient needs. Additionally, the LAL features ActivShield technology, providing built-in UV protection. Established in 1997 and originally named Calhoun Vision, Inc., the company rebranded to RxSight, Inc. in 2017.

Vela Diagnostics Pte. Ltd. specializes in developing advanced tools for sample processing, including sample lysis, nucleic acid extraction, and polymerase chain reaction (PCR). The company has created a platform that enhances clinical, technical, and economic outcomes in diagnostics. Vela Diagnostics provides comprehensive profiling and analytics capabilities, which are essential for medical decision-making and the detection of various bacteria, viruses, and gene mutations. By equipping diagnostic laboratories with innovative solutions, Vela Diagnostics enables them to deliver accurate and relevant research and diagnostic results, ultimately supporting improved patient care.

Moderna is a biotechnology company focused on messenger RNA therapeutics and vaccines. It develops mRNA-based medicines that instruct cells to produce therapeutic proteins or antibodies in vivo, targeting infectious diseases, oncology, cardiovascular diseases, and rare genetic disorders. Founded in 2010 and headquartered in Cambridge, Massachusetts, the company has built a broad pipeline with multiple development candidates across several modalities and a track record highlighted by a COVID-19 vaccine authorized in the United States. Moderna collaborates with major pharmaceutical and research partners, including AstraZeneca, Merck, Vertex, and Alexion, as well as academic institutions such as Harvard University and Karolinska Institutet. It maintains manufacturing collaborations with Lonza for mRNA production and Catalent for fill-finish, and engages with public sector and philanthropic supporters such as BARDA, DARPA, and the Gates Foundation. As of 2025, the company continued expanding its mRNA development program across infectious disease, oncology, cardiovascular, and rare genetic diseases.

Founded in 1998, Emergent BioSolutions is a global life sciences company dedicated to protecting and enhancing life. It specializes in developing, manufacturing, and delivering medical countermeasures against biological, chemical threats, and emerging infectious diseases.

Cue Health Inc. is a healthcare technology company based in San Diego, California, specializing in the development and manufacturing of diagnostic screening devices for home use. Founded in 2010, the company offers a connected diagnostic platform known as the Cue Health Monitoring System, which allows users to conduct self-serve tests that provide lab-quality results. This platform enables individuals to track key health indicators, including inflammation, vitamin D, fertility, influenza, and testosterone, through a user-friendly device that connects to a smartphone app. The Cue app not only displays test results but also integrates data on lifestyle factors such as activity and sleep, facilitating a comprehensive view of health at a molecular level. Additionally, Cue Health provides various services for healthcare professionals, including tools for managing patient test histories and telemedicine consultations. The company's innovative approach empowers consumers and healthcare providers alike to access critical health information easily and effectively.

Paratek Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel tetracycline-based therapies to treat infectious diseases and related public health threats. Its lead programs center on omadacycline, a broad-spectrum tetracycline available in oral and intravenous forms for community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, urinary tract infections, and other serious infections, and sarecycline for acne and rosacea. The company emphasizes expertise in advanced tetracycline chemistry to address antibiotic resistance. Paratek collaborates with industry and academic partners, including licenses with Zai Lab and Allergan, a license with Tufts University to develop products for bacterial diseases, and a cooperative R&D agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline. Founded in 1996 and headquartered in Boston, Paratek aims to bring therapies that improve patient outcomes and address public health challenges.

GenMark Diagnostics, Inc. is a molecular diagnostics company headquartered in Carlsbad, California, specializing in the development and commercialization of its proprietary eSensor electrochemical detection technology. The company’s flagship XT-8 System, which has received FDA 510(k) clearance, allows for the detection of up to 72 distinct biomarkers from a single sample, producing results within 30 minutes. This system supports a variety of molecular diagnostic tests using compact workstations and self-contained, disposable test cartridges. GenMark also offers diagnostic tests for its XT-8 System, including panels for respiratory viruses, cystic fibrosis, thrombophilia risk, warfarin sensitivity, and hepatitis C virus genotyping. The company is actively developing its next-generation platform, the AD-8 System, which aims to further streamline the testing process. GenMark sells its products through direct sales and specialized service organizations across the United States and Europe.

MediWound Ltd. is an integrated biopharmaceutical company based in Yavne, Israel, that specializes in developing, manufacturing, and commercializing innovative therapeutic products for severe burns and chronic wounds. Founded in 2000, the company is known for its flagship product, NexoBrid, which is an FDA-approved biopharmaceutical designed for the removal of eschar in adults with deep partial- and full-thickness thermal burns, offering a less invasive alternative to surgical interventions. MediWound also advances other product candidates, including EscharEx, which has completed Phase II clinical trials for the debridement of chronic and hard-to-heal wounds, and MWPC003 for connective tissue disorders. The company aims to address significant unmet medical needs in these areas and improve patient outcomes.

Summit Therapeutics Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in the discovery, development, and commercialization of novel antibiotics aimed at treating serious infectious diseases. The company focuses on addressing Clostridium difficile infection (CDI) with its lead product candidate, ridinilazole, which is currently undergoing Phase III clinical trials. Additionally, Summit is developing the DDS-01 series to combat infections caused by Neisseria gonorrhoeae and the DDS-04 series targeting Enterobacteriaceae. With operations in the United States and Europe, Summit Therapeutics aims to establish new standards of care for patients while creating value for payors and healthcare providers. Founded in 2003, the company is committed to advancing innovative treatments for infectious diseases.

First Light Diagnostics Inc. is a medical diagnostics company focused on developing automated products for the rapid detection of pathogens responsible for healthcare-associated infections. Based in Chelmsford, Massachusetts, the company offers a benchtop MultiPath analyzer, which is designed for hospital clinical microbiology laboratories and can identify both resistant and sensitive strains of Staphylococcus aureus, as well as various toxins and viruses. Their innovative diagnostic solutions address the increasing demand for accurate and cost-effective testing, which has been shown to significantly reduce hospital infection rates. First Light's proprietary MultiPath detection technology combines the performance of advanced laboratory tests with enhanced affordability and user-friendliness. By providing antimicrobial susceptibility tests that deliver results within hours, the company enables healthcare professionals to administer appropriate antibiotic treatments quickly, ultimately saving lives, reducing healthcare costs, and improving antibiotic stewardship. First Light Diagnostics was incorporated in 2006 and was formerly known as First Light Biosciences Inc. before its name change in January 2019.

Qpex Biopharma is a San Diego-based biopharmaceutical company founded in 2018, focused on developing innovative therapies to address the growing challenge of antimicrobial resistance. The company specializes in creating a pipeline of antibiotic drugs aimed at treating infectious diseases in both inpatient and outpatient settings. With a strong emphasis on the discovery, development, and regulatory approval of anti-infective medicines, Qpex Biopharma leverages its expertise and experience in collaboration with public and private partnerships to meet critical medical needs. The company's mission is to provide effective solutions for healthcare professionals facing the complexities of resistant infections, thereby enhancing treatment options for patients.

BioFactura develops and manufactures high-value biosimilars, biodefense medical countermeasures, and custom novel drugs using its proprietary StableFast Biomanufacturing Platform. The company offers services including expression system development, purification process development, microbial and cell culture process development, custom analytical development, scale-up manufacturing, research consulting, and contract services.

T2 Biosystems, Inc. is an in vitro diagnostics company specializing in the rapid detection of pathogens and biomarkers to enhance patient care. The company employs its proprietary T2 Magnetic Resonance technology, which allows for the detection of various pathogens directly from unpurified patient samples, such as whole blood and urine, without the need for extensive sample preparation. T2 Biosystems offers several diagnostic products, including the T2Dx Instrument, which is designed to identify pathogens associated with sepsis and Lyme disease. Its product lineup includes the T2Candida Panel for detecting Candida species, the T2Bacteria Panel for identifying bacterial pathogens, the T2SARS-CoV-2 Panel for COVID-19 testing, and the T2Resistance Panel for detecting antibiotic resistance markers. Founded in 2006 and headquartered in Lexington, Massachusetts, T2 Biosystems aims to improve clinical outcomes and reduce healthcare costs by enabling faster and more accurate diagnostic testing.

Altimmune is a biopharmaceutical company focused on developing immunotherapies, vaccines, and treatments for liver diseases. Its pipeline includes HepTcell for hepatitis B, NasoShield and AdCOVID for anthrax and COVID-19 respectively, both delivered intranasally, and ALT-801 for non-alcoholic steatohepatitis.

Spectral AI develops proprietary AI algorithms and optical technology to predict wound healing. Its DeepView® Wound Imaging Solution, an FDA Breakthrough Designated system, uses multispectral imaging to distinguish between non-healing and healing tissue invisible to the naked eye. The company aims to provide 'Day One' healing assessments for burn wounds and diabetic foot ulcers.

Integrated BioTherapeutics is a biotechnology company that focuses on discovering novel vaccines and therapeutics for emerging infectious diseases. Its antiviral pipeline includes unique pan-filovirus antibody candidates, vaccines, and a variety of other product candidates for emerging viruses.

Summit Therapeutics Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in the discovery, development, and commercialization of novel antibiotics aimed at treating serious infectious diseases. The company focuses on addressing Clostridium difficile infection (CDI) with its lead product candidate, ridinilazole, which is currently undergoing Phase III clinical trials. Additionally, Summit is developing the DDS-01 series to combat infections caused by Neisseria gonorrhoeae and the DDS-04 series targeting Enterobacteriaceae. With operations in the United States and Europe, Summit Therapeutics aims to establish new standards of care for patients while creating value for payors and healthcare providers. Founded in 2003, the company is committed to advancing innovative treatments for infectious diseases.

Velico Medical, Inc. is a pre-clinical medical technology company based in Beverly, Massachusetts, focused on developing and commercializing innovative products for preparing and storing blood components, particularly platelets and plasma. The company offers FrontlineODP (On Demand Plasma), which enables blood centers to convert plasma into a dried powder format, eliminating the need for freezing. Additionally, Velico Medical provides FrontlinePPS (Platelet Protection System), a technology designed to protect platelets from deterioration during storage. By advancing these technologies, Velico Medical aims to enhance the efficacy of blood products and reduce preventable deaths related to bleeding. The company was formerly known as ZymeQuest and was incorporated in 1991.

Sanofi Pasteur SA is a prominent global developer and manufacturer of vaccines, headquartered in Lyon, France. The company specializes in producing vaccines for a wide range of bacterial and viral diseases, including pertussis, diphtheria, typhoid fever, poliomyelitis, influenza, and mumps. Established in 1990, Sanofi Pasteur has a significant international presence with production facilities located in France, the United States, Canada, China, Thailand, and Argentina. Formerly known as Aventis Pasteur S.A., the company adopted its current name in 2004 and operates as a subsidiary of Sanofi-Aventis, contributing to public health through its extensive vaccine portfolio.

Moderna is a biotechnology company focused on messenger RNA therapeutics and vaccines. It develops mRNA-based medicines that instruct cells to produce therapeutic proteins or antibodies in vivo, targeting infectious diseases, oncology, cardiovascular diseases, and rare genetic disorders. Founded in 2010 and headquartered in Cambridge, Massachusetts, the company has built a broad pipeline with multiple development candidates across several modalities and a track record highlighted by a COVID-19 vaccine authorized in the United States. Moderna collaborates with major pharmaceutical and research partners, including AstraZeneca, Merck, Vertex, and Alexion, as well as academic institutions such as Harvard University and Karolinska Institutet. It maintains manufacturing collaborations with Lonza for mRNA production and Catalent for fill-finish, and engages with public sector and philanthropic supporters such as BARDA, DARPA, and the Gates Foundation. As of 2025, the company continued expanding its mRNA development program across infectious disease, oncology, cardiovascular, and rare genetic diseases.

Soligenix, Inc., a late-stage biopharmaceutical company based in Princeton, New Jersey, focuses on developing and commercializing treatments for rare diseases and serious side effects of cancer therapies, where there is an unmet medical need. The company operates through two segments: Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops therapies such as SGX301 for cutaneous T-cell lymphoma, SGX942 for oral mucositis in head and neck cancer, and proprietary formulations of oral beclomethasone for gastrointestinal disorders. The Public Health Solutions segment works on biodefense vaccines and therapeutics, including RiVax, a ricin toxin vaccine, and SGX943, a therapeutic candidate for antibiotic-resistant and emerging infectious diseases.

Founded in Japan in 1921, Terumo is a global leader in medical technology, committed to contributing to society through healthcare. With over 25,000 associates worldwide and operations in more than 160 countries, the company manufactures and distributes innovative medical solutions including vascular intervention products, cardio-surgical solutions, blood transfusion systems, cell therapy technology, and essential medical products for daily clinical practice.

Spectral AI develops proprietary AI algorithms and optical technology to predict wound healing. Its DeepView® Wound Imaging Solution, an FDA Breakthrough Designated system, uses multispectral imaging to distinguish between non-healing and healing tissue invisible to the naked eye. The company aims to provide 'Day One' healing assessments for burn wounds and diabetic foot ulcers.

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company based in New York, specializing in health security and infectious disease markets. Established in 1995, the company develops antiviral drugs targeting lethal pathogens, including variola virus, which causes smallpox. Its primary product, TPOXX, is an orally administered antiviral treatment specifically designed for human smallpox disease. SIGA is dedicated to creating modern biodefense countermeasures against high-priority viral threats, aiming to prevent and treat diseases such as Ebola, dengue, and Lassa fever. The company primarily generates revenue from the United States market.